Enzyme Replacement Therapy Market Share

  • Report ID: 4455
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Enzyme Replacement Therapy Market Share

Asia Pacific Market Forecast

The Asia Pacific enzyme replacement therapy market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037, owing to the growing number of patient population suffering from rare disorders, rising disposable income, growth in the healthcare sector, and an increase in government support. According to the Economist Intelligence Unit, 258 million individuals in Asia and the Pacific region suffer from rare diseases.

Europe Market Forecast

On the other hand, in 2023, Europe held the second-largest share of the worldwide market. The increase can be credited primarily to supportive regulatory policies in a few European nations for different infrequent lysosomal ailments, including Gaucher disease, MPS, and others. As per F1000 Research Ltd., the Polish National Health Fund, for instance, implemented a national drug program in 2019, with the first remuneration in ERT for Fabry disease. Furthermore, rapid advancements in medical infrastructure and a growing preference for therapeutic approaches for rare diseases drive market expansion in this region.

Research Nester
Enzyme-Replacement-Therapy-Market Size
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4455
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of enzyme replacement therapy is assessed at USD 12.03 billion.

The enzyme replacement therapy market size was valued at USD 11.42 billion in 2024 and is anticipated to reach USD 26.48 billion by the end of 2037, registering around 6.8% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by rise in prevalence of rare disease, growing government spending on healthcare infrastructure, growing cases of Pompe disease, and others.

Asia Pacific industry is set to dominate majority revenue share by 2037, owing to growing number of patient population suffering from rare disorders along with rising disposable income, growth in the healthcare sector, and an increase in government support in the region.

The major players in the market include BioMarin, Leadiant Biosciences, Inc., Pfizer Inc., Sanofi Aventis, AbbVie Inc., Takeda Pharmaceutical Company Limited, JCR Pharmaceutical Co., Ltd., AstraZeneca plc, Clinigen Limited, Teijin Limited.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample